IO Biotech and Merck to Evaluate Neoadjuvant and Adjuvant IO102-IO103 With KEYTRUDA in Ph 2 Trial in Patients with Resectable Tumors November 16, 2022
IGM Biosciences and ADC Therapeutics to Evaluate Imvotamab (IGM-2323) + ZYNLONTA in R/R B-cell NHL Patients November 16, 2022
Tessa Therapeutics, Baylor College of Medicine Execute Agreement For Global Commercial Rights to ‘Off-the-Shelf’ CAR-T Platform November 16, 2022
Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors November 16, 2022
Geneos Therapeutics Announces Positive Clinical Data for Personalized Therapeutic Cancer Vaccines in Ongoing Liver Cancer Trial November 16, 2022
Incyte And Mirati Therapeutics Enter To Evaluate INCB99280 And Adagrasib In Patients With KRASG12C-Mutated Solid Tumors November 16, 2022
MGFB announces agreement with Mayo Clinic for development of novel therapeutic cancer vaccines November 16, 2022
Eucure Biopharma Announces Partnership with ISU ABXIS for the Development of Tri-specific Antibodies using YH003 Antibody Sequence November 16, 2022
Exelixis and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop ADU-1805 November 16, 2022
Obsidian Therapeutics Announces Extension of Multi-Year Collaboration Agreement with BMS November 4, 2022
Candel Therapeutics Partners with the University of Pennsylvania’s Center for Cellular Immunotherapies to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy in Solid Tumor Models November 4, 2022
Adaptimmune Enhances Its Pipeline of Wholly Owned Cell Therapies for Cancer with Transfer of PRAME and NY-ESO Target Programs from GSK November 4, 2022
Zentalis Pharmaceuticals Announces First ZN-c3 Clinical Development Collaboration with Pfizer November 2, 2022
HOOKIPA Announces Strategic Collaboration And License Agreement With Roche To Develop Novel Arenaviral Immunotherapy For KRAS-Mutated Cancers October 26, 2022
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Evaluate ERAS-007 and Palbociclib Combination October 26, 2022
Kite And Refuge Biotechnologies Announce Exclusive License Agreement For Investigational Gene Expression Platform For Blood Cancers October 26, 2022
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab October 26, 2022
Gilead And MacroGenics Announce Oncology Collaboration To Develop Bispecific Antibodies October 26, 2022
Mirati Therapeutics & Aadi Bioscience Partner to Evaluate Adagrasib + Nab-sirolimus in Advanced NSCLC and Other Solid Tumors patients with a KRAS[G12C] Mutation October 19, 2022
VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Balstilimab in a Ph 2 Study in Primary Glioblastoma Patients October 19, 2022
Tavros Therapeutics and Vividion Therapeutics Announce Strategic Collaboration to Discover and Enhance Targeted Oncology Programs October 19, 2022
